Today’s Hottest: WVS Financial Corp. (NASDAQ:WVFC), Harvest Capital Credit Corporation (NASDAQ:HCAP), SunEdison (NYSE:SUNE), Inovio Pharmaceuticals (NASDAQ:INO)

Posted by on Feb 23, 2016

Sun Bancorp Inc. (NASDAQ:SNBC) shares increased 0.49% in last trading session and ended the day at $20.55. SNBC has a return on assets of 0.40%. Sun Bancorp Inc. (NASDAQ:SNBC) quarterly performance is -4.86%.

Zacks Investment Research restated their hold rating on shares of Sun Bancorp, Inc. /NJ (NASDAQ:SNBC) in a research report report published on Monday morning, MarketBeat Ratings reports.

WVS Financial Corp. (NASDAQ:WVFC) ended the last trading day at $11.61. Company weekly volatility is calculated as 0.36% and price to cash ratio as 2.68. WVS Financial Corp. (NASDAQ:WVFC) showed a weekly performance of -1.13%.

On 22 February, Harvest Capital Credit Corporation (NASDAQ:HCAP) shares increased 0.20% and was closed at $10.11. HCAP EPS growth in last 5 year was -5.02%. Harvest Capital Credit Corporation (NASDAQ:HCAP) year to date (YTD) performance is -12.01%.

Harvest Capital Credit Corporation (NASDAQ:HCAP) announced that it will report financial results for the fiscal quarter and year ended December 31, 2015 before market open on Tuesday, March 15, 2016. The company will hold a conference call to discuss the results at 11:00 a.m. ET that morning.

SunEdison, Inc. (NYSE:SUNE) shares remains unchanged in last trading session and ended the day at $1.43. SUNE Gross Margin is 17.60% and its has a return on assets of -7.30%. SunEdison, Inc. (NYSE:SUNE) quarterly performance is -56.00%.

On 18 February, SunEdison, Inc. (NYSE:SUNE), provided an update on its previously articulated strategy to refocus its Solar Materials operations on asset-light proprietary silicon production technologies via partnerships and joint ventures designed to enhance profitability while preserving high efficiency, cost effective solar panels supply to its downstream solar development platform.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) caters to the Healthcare space. It has a net profit margin of -50.40% and weekly performance is 6.54%. On the last day of trading company shares ended up at $6.68.

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced that preclinical testing of its synthetic vaccine for the Zika virus induced robust and durable immune responses, demonstrating the potential for a SynCon vaccine to prevent and treat infections from this harmful pathogen. Health authorities have observed neurological and autoimmune complications potentially associated with Zika virus, including microcephaly in newborns and Guillain-Barre syndrome. Inovio is developing its Zika vaccine with GeneOne Life Sciences (KSE: 011000) and academic collaborators.

Leave a Reply

Your email address will not be published. Required fields are marked *